FDA expands approval for GSK’s RSV vaccine to cover younger at-risk adults
Posted:
The Food and Drug Administration expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.
Based on research completed as part of a multi-year collaboration with Nokia Bell Labs, biomedical engineers at Duke University are developing a solution. Using a custom-built optical coherence tomography (OCT) imaging system together with artificial intelligence (AI) models grounded in…
Rare conditions in the ICU include both formally classified rare diseases and conditions that occur infrequently in critical care settings. These patients often face delayed diagnosis, limited specialist expertise and complex multisystem involvement, all of which contribute to poorer outcomes…
Attendees
Sponsors and Exhibitors
Contact us